HAW PAR CORP LTD (H02) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of HAW PAR CORP LTD stock S$14.26, price S$12.79, upside +11.5%, quality 68 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
HAW PAR CORP LTD
H02 · SGThe stock costs 10% less than our calculation considers fair.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.
How to read this chart
60‑month range 7.26 SGD – 17.81 SGD · fair‑value band 10.70 SGD – 21.82 SGD · the 12.79 SGD price screens below the 14.26 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 1, 2026.
Every Wednesday you see whether HAW PAR CORP is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally.
Show moreShow less
It manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands; and invests in quoted securities. The company also owns and leases various investment properties.
In addition, it provides family and tourist oriented leisure activities primarily in the form of oceanariums. Further, the company is involved in the property development; and owning and letting properties; letting out of office spaces; and management support services.
Haw Par Corporation Limited was incorporated in 1969 and is based in Singapore.
Stock analysis
HAW PAR CORP LTD (H02) currently trades at 12.79 SGD, while our model-based Fair Value estimate is 14.26 SGD, implying the stock looks roughly 10% undervalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of 24.72 SGD per share, and 13 of the 26 models we run sit above the 12.79 SGD price.
Bear case: the Economic Profit group reads lowest at 6.44 SGD, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 10.70 SGD (bear) to 21.82 SGD (bull), the price of 12.79 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.
HAW PAR CORP LTD reported revenue of 230M SGD in FY2025 versus 141M SGD in FY2021, a compound +13.0%/yr. Reported net income was 265M SGD in FY2025, compounding +24.6%/yr from FY2021.
Key figures
Market cap 2.8B SGD (≈ $2.2B) Mid · P/E ratio 12.3 · P/S ratio 12.9 · EPS (TTM) 1.04 SGD · Dividend yield 3.1% · Net margin 104% · Return on equity 5.2% · Return on assets (EBIT) 1.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 11%, H02 screens cheaper than that median.
Fair Value models
All 26 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch H02, get fair value alerts →
Compare HAW PAR CORP LTD with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- Stock screener with 62 metrics
- Valuation of the Singapore market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Bristol-Myers Squibb Company BMY | $61.71 | $75.91 | +23% | vs H02 |
| Gilead Sciences, Inc GILD | $167.47 | $187.75 | +12% | vs H02 |
| Amgen Inc AMGN | $461.26 | $507.39 | +10% | vs H02 |
| AbbVie Inc ABBV | $286.00 | $259.62 | −9% | vs H02 |
| Novartis AG NOVN | CHF 134.26 | CHF 120.96 | −10% | vs H02 |
| Merck & Co MRK | $144.67 | $129.26 | −11% | vs H02 |
| Pfizer Inc PFE | $30.00 | $24.87 | −17% | vs H02 |
| Roche Holding RO | CHF 401.60 | CHF 326.56 | −19% | vs H02 |
| Johnson & Johnson, JNJ | $266.17 | $168.85 | −37% | vs H02 |
| Eli Lilly and Company LLY | $1,409 | $749.92 | −47% | vs H02 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is HAW PAR CORP LTD (H02) overvalued or undervalued?
What is the fair value of H02?
What is the quality score of H02?
What is the price target for HAW PAR CORP LTD (H02)?
What is the HAW PAR CORP LTD stock forecast for 2026?
What is the revenue of HAW PAR CORP LTD (H02)?
Does HAW PAR CORP LTD pay a dividend?
What growth is priced into HAW PAR CORP LTD (H02)?
What discount rate (WACC) does the fair value of H02 use?
What is a reverse DCF?
How much growth has HAW PAR CORP LTD (H02) delivered so far?
How fast is the sector of HAW PAR CORP LTD (H02) growing?
What is the free cash flow yield of HAW PAR CORP LTD (H02)?
What is the intrinsic value of HAW PAR CORP LTD (H02)?
Is HAW PAR CORP LTD stock overvalued or undervalued in 2026?
Is fair value the same as the market price of H02?
How much is HAW PAR CORP LTD worth?
What do the bullish and bearish scenarios say about H02?
What is the P/E ratio of H02?
How solid is the balance sheet of HAW PAR CORP LTD (H02)?
How far is H02 from its 52-week high?
Which stocks are comparable to HAW PAR CORP LTD?
Is HAW PAR CORP LTD stock attractive at the current price?
How is the fair value of H02 calculated?
Is it still worth investing in stocks now?
What is the share price of HAW PAR CORP LTD (H02)?
What should I pay attention to with HAW PAR CORP LTD right now?
Key figures of HAW PAR CORP LTD
How large is the market capitalisation of HAW PAR CORP LTD (H02)?
What is the P/S ratio of HAW PAR CORP LTD (H02)?
What are the earnings per share of HAW PAR CORP LTD (H02)?
What is the dividend yield of HAW PAR CORP LTD (H02)?
What is the net margin of HAW PAR CORP LTD (H02)?
What is the return on equity of HAW PAR CORP LTD (H02)?
What is the EBIT return on assets of HAW PAR CORP LTD (H02)?
What is the operating margin of HAW PAR CORP LTD (H02)?
How fast is revenue growing at HAW PAR CORP LTD (H02)?
How fast are earnings growing at HAW PAR CORP LTD (H02)?
Watch HAW PAR CORP LTD in the live analysis
One click puts HAW PAR CORP LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.